Nanoscale Tool Allows Scientists To Study Membrane Proteins One At A Time

Thursday, March 6, 2008

Isolation Chamber A new tool developed at Rockefeller allows scientists to study membrane proteins individually, or in pairs, to see how they interact with other molecules. The scientists use an electron microscope to take images of isolated NABBs and categorize the orientation of the receptors they contain as either antiparallel (top) or parallel (bottom).

of the myriad transmembrane receptors that direct cell activity by reacting to molecules outside the cell and activating signals inside the cell.

“Today it is impossible to know exactly what a single protein on the surface of a cell that has thousands of other proteins is doing. It might be acting on its own or binding to one or more other proteins,” says Thomas Sakmar, Richard M. and Isabel P. Furlaud Professor and head of the laboratory and the study’s senior investigator. “With this tool, we can control the receptor’s membrane environment and test all possibilities of interaction with ligands, other receptors or other proteins. It’s one way to figure out how a complex system works.”

Previously, researchers studied the functions of such proteins by investigating literally millions of them floating together in a soup created when cell membranes are broken apart and solubilized chemically. But this method of studying proteins is problematic, the researchers say: The membrane protein mixtures tend to be inhomogeneous and it is difficult — partially due to poor stability of the isolated proteins — to purify them in their active state in order to understand what the receptors are doing individually.

The solution, devised by Sakmar, first author Sourabh Banerjee, a graduate student in the Tri-Institutional Chemical Biology Program, and Thomas Huber, a postdoc, arose as the team searched for a way to exquisitely catalogue the functions of individual G-protein-coupled receptors (GPCRs), a large family of transmembrane proteins that are involved in many diseases and are often the target of medicinal agents. The structure they built was developed using a hard-working human transport particle, the high-density lipoprotein (HDL), as a model system. This flat, circular structure is essentially a complex of phospholipids belted together by apolipoprotein A-I (apo A-I) to carry cholesterol and lipids through blood to the liver.

Assuming that evolutionary forces might have already optimized a biological solution to an engineering problem, Huber suggested using apo A-I from zebrafish. “Based on the sequence of zebrafish apo A-I, we thought that it may yield structurally homogeneous discs,” Banerjee says. So in their NABB, zebrafish apo A-I (known as zap1) forms a belt that makes two layers of lipids stick together — like the seaweed that keeps sticky rice together in sushi.

They then devised a method to trigger rapid self-assembly of these disc-like nanoparticles from mixtures of zap1, lipids and extracted cellular membrane proteins. “We have made it fairly straightforward to make these structures and they form in less than an hour,” says Banerjee, who coined the term NABBs.

The team visualized individual antibody fragments bound to the receptors with an electron microscope. And, as a proof of principle, they experimented with rhodopsin, a prototypical GPCR. They found that rhodopsin was remarkably stable in NABBs — as stable as in its native membranes. They also found that it doesn’t require a “dimer,” or union of two rhodopsin receptors, to produce a response — as many scientists had argued — but that rhodopsin can be activated in its monomeric form.

“Each protein is very happy inside its own disc and the beauty is that both sides of these receptors, the part that is inside the cell and the part that is outside, are exposed to whatever you want to test it with,” Sakmar says. “That way we can use it to monitor what happens on both sides of the cell membrane.”

“This tool can be used for a wide variety of membrane proteins,” Banerjee says. “We think it will be important for high-throughput screening for new drugs that can bind to membrane proteins involved in disease.”

Source: Rockefeller University